DAE HWA Pharmaceutical Co., Ltd. (KOSDAQ:067080)
10,960
+360 (3.40%)
At close: Sep 4, 2026
DAE HWA Pharmaceutical Revenue
DAE HWA Pharmaceutical had revenue of 41.29B KRW in the quarter ending June 30, 2026, with 14.82% growth. This brings the company's revenue in the last twelve months to 148.75B, up 0.14% year-over-year. In the year 2025, DAE HWA Pharmaceutical had annual revenue of 143.06B, down -4.25%.
Revenue (ttm)
148.75B
Revenue Growth
+0.14%
P/S Ratio
1.36
Revenue / Employee
482.97M
Employees
308
Market Cap
201.91B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 143.06B | -6.35B | -4.25% |
| Dec 31, 2024 | 149.41B | 8.05B | 5.69% |
| Dec 31, 2023 | 141.36B | 9.45B | 7.16% |
| Dec 31, 2022 | 131.91B | 14.75B | 12.59% |
| Dec 31, 2021 | 117.16B | 7.81B | 7.15% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| NOVAREX | 404.26B |
| Ahn-Gook Pharmaceutical | 345.08B |
| Cosmax Nbt | 335.18B |
| Kyung Dong Pharmaceutical | 201.12B |
| GC WellBeing | 192.21B |
| HYUNDAI BIOLAND | 140.70B |
| Vivozon Pharmaceutical | 50.34B |
| HEM Pharma | 16.14B |